Evidence map›Paper›PMID 42240760›Full record

ArticleMolecular diversity2026

Structural disruption of VKORC1 by resistance mutations reveals a conserved hydrophobic pattern essential for warfarin binding: insights from molecular dynamics analyses.

Nolan Chatron, Sionfoungo Daouda Soro, Etienne Benoit, Virginie Lattard

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Nolan ChatronUSC1233 RS2GP, INRAE, VetAgro Sup, University of Lyon, F-69280, Marcy l'Étoile, France. nolan.chatron@vetagro-sup.fr.ORCID http://orcid.org/0000-0002-7973-4896
Sionfoungo Daouda SoroUSC1233 RS2GP, INRAE, VetAgro Sup, University of Lyon, F-69280, Marcy l'Étoile, France.ORCID http://orcid.org/0009-0008-0429-2465
Etienne BenoitUSC1233 RS2GP, INRAE, VetAgro Sup, University of Lyon, F-69280, Marcy l'Étoile, France.ORCID http://orcid.org/0000-0002-7076-2911
Virginie LattardUSC1233 RS2GP, INRAE, VetAgro Sup, University of Lyon, F-69280, Marcy l'Étoile, France.ORCID http://orcid.org/0000-0002-3371-0952

Funding

Agence Nationale de la Recherche ANR-18-CE20-0025
6 · The paper itself

Abstract

Vitamin K epoxide reductase (VKORC1) catalyzes the reduction of vitamin K epoxide to quinone and hydroquinone, a cofactor essential for the activation of clotting factors. Mutations in VKORC1 are known to confer resistance to vitamin K antagonists (VKAs) such as warfarin in both humans and rodents, yet the structural mechanisms underlying these resistances remain poorly understood. Using AlphaFold3-predicted structures, molecular docking and molecular dynamics simulations, we investigated the effects of four major resistance-causing mutations - W59G and L128S in Mus musculus, L120Q and Y139C in Rattus norvegicus - on VKORC1 structure and warfarin binding. Three mutations (W59G, L120Q and L128S) disrupted a hydrophobic cluster linking the ER luminal loop to transmembrane helices TM3-TM4, inducing and ER loop drift and altering helices orientation. These structural changes reduced warfarin affinity compared to the wild-type enzyme. In contrast, the Y139C mutation caused minimal perturbation and preserved wild-type binding energy, suggesting that it may confer resistance through a different mechanism. Collectively, six hydrophobic residues (V54, W59, L120, I123, L124, L128) were identified as a conserved structural pattern critical for VKORC1 stability and inhibitor sensitivity. This integrative structural study provides a mechanistic framework for understanding VKA resistance in VKORC1. It highlights a hydrophobic core essential for enzyme integrity and drug binding, offering a molecular basis for monitoring emerging mutations and for designing next-generation anticoagulants active against resistant VKORC1 variants.

Indexed as

Anticoagulant resistanceHydrophobic patternMolecular modelingMutationsVKORC1

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.